Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The clinical perspective on late-onset depression in European real-world treatment settings.
Bartova L, Fugger G, Dold M, Kautzky A, Bairhuber I, Kloimstein P, Fanelli G, Zanardi R, Weidenauer A, Rujescu D, Souery D, Mendlewicz J, Zohar J, Montgomery S, Fabbri C, Serretti A, Kasper S. Bartova L, et al. Among authors: fugger g. Eur Neuropsychopharmacol. 2024 Jul;84:59-68. doi: 10.1016/j.euroneuro.2024.03.007. Epub 2024 Apr 27. Eur Neuropsychopharmacol. 2024. PMID: 38678879 Free article.
Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD).
Dold M, Bartova L, Fugger G, Kautzky A, Souery D, Mendlewicz J, Papadimitriou GN, Dikeos D, Ferentinos P, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S. Dold M, et al. Among authors: fugger g. Int J Neuropsychopharmacol. 2018 Jun 1;21(6):539-549. doi: 10.1093/ijnp/pyy009. Int J Neuropsychopharmacol. 2018. PMID: 29860382 Free PMC article.
Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study.
Dold M, Bartova L, Fugger G, Mitschek MMM, Kautzky A, Frey R, Montgomery S, Zohar J, Mendlewicz J, Souery D, Fabbri C, Serretti A, Kasper S. Dold M, et al. Among authors: fugger g. Eur Neuropsychopharmacol. 2020 Dec;41:70-80. doi: 10.1016/j.euroneuro.2020.09.636. Epub 2020 Oct 9. Eur Neuropsychopharmacol. 2020. PMID: 33046351
The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.
Bartova L, Fugger G, Dold M, Kautzky A, Swoboda MMM, Rujescu D, Zohar J, Souery D, Mendlewicz J, Montgomery S, Fabbri C, Serretti A, Kasper S. Bartova L, et al. Among authors: fugger g. Int J Neuropsychopharmacol. 2022 Feb 11;25(2):118-127. doi: 10.1093/ijnp/pyab066. Int J Neuropsychopharmacol. 2022. PMID: 34637516 Free PMC article.
Silexan for treatment of anxiety and depression in the context of COVID-19.
Bartova L, Dold M, Fugger G, Weidenauer A, Rujescu D, Kasper S. Bartova L, et al. Among authors: fugger g. Eur Neuropsychopharmacol. 2023 May;70:47-48. doi: 10.1016/j.euroneuro.2023.02.015. Epub 2023 Feb 23. Eur Neuropsychopharmacol. 2023. PMID: 36867894 Free PMC article. No abstract available.
Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder.
Bartova L, Fugger G, Dold M, Kautzky A, Fanelli G, Zanardi R, Albani D, Weidenauer A, Rujescu D, Souery D, Mendlewicz J, Montgomery S, Zohar J, Fabbri C, Serretti A, Kasper S. Bartova L, et al. Among authors: fugger g. J Affect Disord. 2023 Jul 1;332:105-114. doi: 10.1016/j.jad.2023.03.068. Epub 2023 Mar 22. J Affect Disord. 2023. PMID: 36958488 Free article.
33 results